Biogen Pharmachem Industries Ltd

Despite a broad market rally and sectoral strength, Biogen Pharmachem Industries Ltd has plunged to a fresh 52-week low of Rs 0.43 on 11 May 2026, extending its recent downward trajectory amid persistent selling pressure.

A sharp decline in Biogen Pharmachem Industries Ltd has pushed the stock to a fresh 52-week low of Rs 0.44 on 8 May 2026, marking a 47.06% drop over the past year and signalling intensified selling pressure despite some recent gains in the broader market indices.

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Sep 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are current as of 08 May 2026, providing investors with an up-to-date view of the company’s position in the market.

Biogen Pharmachem Industries Ltd’s stock price declined to a fresh 52-week low of Rs.0.46 on 05 May 2026, marking a significant downturn amid broader market pressures and company-specific financial indicators. The stock’s performance over the past year has been notably weaker than the benchmark Sensex, reflecting ongoing concerns about its financial health and valuation metrics.

A sharp decline has pushed Biogen Pharmachem Industries Ltd to a fresh 52-week low of Rs 0.46 on 28 Apr 2026, marking a 47.25% drop over the past year and underscoring persistent selling pressure despite pockets of financial improvement.

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.

Biogen Pharmachem Industries Ltd’s share price declined sharply to a new 52-week low of Rs.0.48 on 17 April 2026, marking a significant downturn in the stock’s performance amid broader market gains.

Biogen Pharmachem Industries Ltd is rated 'Strong Sell' by MarketsMOJO, a rating that was last updated on 08 Sep 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 15 April 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trend, and technical outlook.

A sharp decline has pushed Biogen Pharmachem Industries Ltd to a fresh 52-week low of Rs 0.49 on 10 Apr 2026, marking a 45.65% drop over the past year despite a rising Sensex. The stock’s underperformance contrasts starkly with the broader market rally, highlighting persistent pressures on this micro-cap NBFC.

Biogen Pharmachem Industries Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 08 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Sep 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 19 March 2026, providing investors with the latest insights into its performance and valuation.

Biogen Pharmachem Industries Ltd has touched a new 52-week low today, closing at Rs.0.5, marking a significant decline in its share price amid a challenging market environment and subdued financial performance.

Biogen Pharmachem Industries Ltd has declined to a fresh 52-week low of Rs.0.55, marking a significant downturn in its stock performance amid a challenging market environment and subdued financial indicators.

Biogen Pharmachem Industries Ltd is rated 'Strong Sell' by MarketsMOJO. This rating was last updated on 08 Sep 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 05 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Biogen Pharmachem Industries Ltd., a micro-cap non-banking financial company with a market capitalisation of ₹62.00 crores, has reported a return to profitability in Q3 FY26 (October-December 2025) after a loss-making previous quarter. The company posted a net profit of ₹0.46 crores for the quarter ended December 2025, marking a sharp turnaround from a loss of ₹0.49 crores in Q2 FY26. However, the stock continues to face significant headwinds, trading at ₹0.69 and down 34.91% over the past year, significantly underperforming both the Sensex and its NBFC sector peers.